Who is sponsoring ILOCOVID?

ILOCOVID is sponsored by Hamad Medical Corporation.

What condition does ILOCOVID study?

ILOCOVID studies COVID-19, ARDS, Human, Hypoxemic Respiratory Failure.

What drugs are being tested in ILOCOVID?

Interventions: Inhaled ILOPROST.

What is the status of ILOCOVID?

ILOCOVID is currently COMPLETED.

Last reviewed 2022-03-29 · How we verify

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure (ILOCOVID)

NCT04445246 PHASE2 COMPLETED

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.

Details

Lead sponsor	Hamad Medical Corporation
Phase	PHASE2
Status	COMPLETED
Enrolment	40
Start date	Sat May 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

COVID-19
ARDS, Human
Hypoxemic Respiratory Failure

Interventions

Inhaled ILOPROST

Countries

Qatar